The Business

Surepharm provides outsourced formulation, development, manufacturing and packaging of pharmaceutical products for its customers in the UK and overseas. Surepharm currently specialises in producing solid dose tablets and capsules, including niche medicines, controlled drugs and veterinary products.

The Deal

Chiltern Capital invested in 2022, acquiring the majority stake in the business, supporting the incoming Chair and management team to deliver the ambitious business plan.

“Surepharm has been a trusted supplier of pharmaceutical products and services to its customers for many years. With the support of Chiltern, we will be able to expand both the capacity and capabilities of the company to enhance our offering and to drive faster growth. It’s a very exciting time to be joining the company.”

Richard Yarwood, Chair

purchased adobestock 117583591
The Plan

Chiltern’s investment, and the introduction of a sector expert management team, will support Surepharm to enhance its formulation and development offering, as well as providing funding for capex investment into new dosage forms. Together with investment in the sales and marketing function, this will enable Surepharm to provide both existing and new customers with an end-to-end service, from drug development through to a packaged commercial product across a broad range of product types.